Format

Send to

Choose Destination

See 1 citation found using an alternative search:

J Crohns Colitis. 2015 Dec;9(12):1096-107. doi: 10.1093/ecco-jcc/jjv152. Epub 2015 Sep 7.

Immunogenicity and Safety of Influenza Vaccine in Inflammatory Bowel Disease Patients Treated or not with Immunomodulators and/or Biologics: A Two-year Prospective Study.

Author information

1
Université Paris Descartes, Sorbonne Paris Cité, Paris, France Assistance Publique Hôpitaux de Paris (AP-HP), Hôpital Cochin, CIC Cochin-Pasteur, Paris, France INSERM, CIC 1417, Paris, France INSERM, F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), Paris, France odile.launay@cch.aphp.fr.
2
AP-HP, Hôpital Cochin, Service de gastro-entérologie, Paris, France.
3
AP-HP, Hôpital Cochin, Service de virologie, Paris, France.
4
Assistance Publique Hôpitaux de Paris (AP-HP), Hôpital Cochin, CIC Cochin-Pasteur, Paris, France.
5
CHU Nantes, Hôtel Dieu, Nantes, France.
6
Service d'Hépatogastroentérologie, Hôpital Nord, Amiens, France.
7
Hôpital de l'Archet, Fédération d'Hépatogastroentérologie et de nutrition clinique, Nice, France.
8
Service Hépatogastroentérologie et Nutrition, Hôpital Charles Nicolle, Rouen, France.
9
INSERM, F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), Paris, France INSERM-CHRU de Lille, CIC 1403, Lille, France.
10
Hôpital Beaujon, Service de Gastroentérologie et Assistance Nutritive, Clichy, France.
11
Service de Gastroentérologie, Hôpital Bichat Claude Bernard, Paris, France.
12
INSERM, F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), Paris, France INSERM, CIC de Montpellier, Hôpital Saint Eloi, Montpellier, France.
13
Service d'Hépatogastroentérologie, Hôpital Haut-Lévêque, Pessac, France.
14
Service de Gastroentérologie, CHU Jean Minjoz, Besançon, and Service d'Hépatogastroentérologie, Hôpital Claude Huriez, Lille, France.
15
Service d'Hépato-gastroentérologie, Hôpital Saint-André, Bordeaux, France.
16
Service de Gastroentérologie, AP-HP, Hôpital Saint-Louis, Paris, France.
17
Service de Médecine Digestive et Hépatobiliaire, CHU Estaing, Clermont-Ferrand, France.
18
Hôpitaux Universitaires de Strasbourg, Service d'Hépato gastroentérologie, Hôpital de Hautepierre, INSERM U1113, Strasbourg, France.
19
INSERM, F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), Paris, France CHU Saint Etienne, Service des Maladies Infectieuses et tropicales, Saint Etienne, France.
20
INSERM, F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), Paris, France Antiviral Immunity, Biotherapy and Vaccine Unit, Infection and Epidemiology Department, Institut Pasteur, Paris, France.
21
Université Paris Descartes, Sorbonne Paris Cité, Paris, France INSERM, F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), Paris, France Hôpital Européen Georges Pompidou, Service d'Immunologie Biologique, INSERM, UMR_S 970, PARCC, Paris, France.
22
Université Paris Descartes, Sorbonne Paris Cité, Paris, France AP-HP, Hôpital Cochin, Service de virologie, Paris, France.
23
Service de médecine interne, AP-HP; Hôpital Ambroise Paré, Université de Versailles Saint-Quentin-en-Yvelines, Boulogne-Billancourt, France.
24
Service de Gastroentérologie, AP-HP, Hôpital Saint-Antoine et INSERM/UMRS 7203, UPMC Université de Paris VI, Paris, France.
25
Département de santé publique, AP-HP, Hôpital Saint-Antoine, Paris, France Université Pierre et Marie Curie, UMR-S 1136, Paris, France INSERM, U1136, Paris, France.

Abstract

BACKGROUND AND AIMS:

Data on the efficacy and safety of seasonal influenza vaccines in patients with inflammatory bowel disease (IBD) remain scarce. The aim of the study was to evaluate the impact of immunosuppressive (IS) therapeutics on serological response to 2-year influenza vaccination in IBD adults.

METHODS:

A multicentre prospective study performed in 255 IBD adults (18-64 years) receiving the trivalent influenza vaccine in the years 2009-2010 and 2010-2011. Haemagglutination inhibition (HI) titres were assessed before and 3 weeks and 6 months after vaccination.

RESULTS:

At inclusion, 31 patients were receiving no IS treatment (Group A), 77 were receiving IS treatment without anti-TNF (Group B) and 117 were receiving anti-tumour necrosis factor (TNF) treatment with or without IS treatment (Group C). Three weeks after the first vaccination, rates of seroprotection were 77, 75 and 66% for strain A/H1N12007 (p = 0.35), 77, 68 and 52% for strain A/H3N2 (p = 0.014) and 97, 96 and 95% for strain B (p = 0.99) in Groups A, B and C, respectively. Seroconversion rates for A/H1N12007 (67, 64 and 54%; p = 0.28), A/H3N2 (63, 50 and 41%; p = 0.074) and strain B (63, 76 and 60%; p = 0.078) were not significantly different among treatment groups. At 6 months after vaccination, seroprotection rates were lower in Group C compared with Groups A and B. Comparable results were observed for the second year of vaccination. No impact on Harvey-Bradshaw and Mayo scores was detected.

CONCLUSIONS:

Influenza vaccine yielded high seroprotection rates in IBD patients. Persistence of seroprotection was lower in patients with anti-TNF treatment. ClinicalTrials.gov, number NCT01022749.

KEYWORDS:

Vaccine immune response; anti-TNF; safety

PMID:
26351392
DOI:
10.1093/ecco-jcc/jjv152
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center